THE FEATURES OF THE COURSE OF HEPATITIS B IN HIV-INFECTED INDIVIDUALSS AND ITS TREATMENT
DOI:
https://doi.org/10.11603/1681-2727.2018.3.9422Keywords:
HBV infection, HIV infection, combined infection, features of the course, treatmentAbstract
The purpose of the study - based on the analysis of literary information to highlight the features of the course of hepatitis B in HIV-infected individuals, as well as the basic principles of treatment of these patients and drugs that used for these purpose in the world and in Ukraine.
HIV and parenteral viral hepatitis belong to socially significant diseases that can significantly affect the demographic situation in the country. Ukraine belongs to countries with an average prevalence of HBV, but there is no data on the frequency of detecting HBV markers in patients with HIV.
From the published data of several studies, the mutual influence of HIV and HBV on the course of both HIV infection and chronic hepatitis B (CHBV) is known. The incidence of AIDS and AIDS-related deaths is significantly higher in people with combined HBV / HIV infection, which is now a global public health problem.
The basic principles of treatment for patients with CHBV / HIV are consistent with those in patients with HBV-monoinfection. According to the published results of several epidemiological studies, the main factor leading to chronic HCV is the level of HBV DNA in patients’ blood or viral load. Therefore, the goal of treatment is to suppress HBV replication to reduce inflammation and to stop or slow down the progression of fibrosis, thereby preventing the late complications of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). All these patients should receive antiretroviral therapy (ART), regardless of the number of CD4 + lymphocytes.
According to published results of a number of studies, the terminal stage of liver disease is a frequent cause of hospitalization and death of patients with combined HBV / HIV infection. But there are still controversial therapies for people with combined HIV and parenteral viral hepatitis. Therefore, the choice of optimal tactics for the management of these patients and the timely appointment of adequate treatment remains relevant.
References
WHO. (2017). Global Hepatitis Report. [E-resource]. Retrieved from: http://apps.who.int/iris/bitstream/handle/10665/255017/WHO-HIV-2017.06-eng.pdf;jsessionid=CA38A4EABD4E35A52C6364B08AA04D1C?sequence=1
Epidemichna sytuatsiya z VIL-infektsiyi v Ukrayini [The epidemic situation with HIV in Ukraine. (November 27th 2017). [E-resource]. Retrieved from: http://moz.gov.ua/article/news/epidemichna-situacija-z-vil-infekcii-v-ukraini- [In Ukrainian].
VIL-infektsiya v Ukrayini [HIV infection in Ukraine]. (2016). Informatsiynyy byuleten. Kyiv, 45. 130 p. [In Ukrainian].
Andreychyn, M.A., Zhyvytsya, D.H. (2013). Epidemiolohichni ta kliniko-patohenetychni zvyazky VIL-infektsiyi i hemokontaktnykh virusnykh hepatytiv [Epidemiological and clinical-pathogenetic links of HIV infection and hemocontact viral hepatitis]. Virusni khvoroby. VIL-infektsiya/SNID: mat. Vseukrayinskoyi nauk.-prakt. konf. z mizhnar. uchastyu i plenumu Asotsiatsiyi infektsionistiv Ukrayiny (3-4 zhovtnya 2013 r., m. Alushta). Ternopil: TDMU Ukrmedknyha, 3-4. [In Ukrainian].
Andreychyn, M.A., Vasylyshyn, Z.P., Vynohrad, N.O. ; za red. Kolesnikovoyi, I.P. (2012). Epidemiolohiya : pidruchnyk dlya stud. vyshchykh med. navch. zakladiv [Epidemiology: A textbook for students of higher medical schools]. Vinnytsya: Nova Knyha, 576 p. [In Ukrainian].
Lee, H., Park, W. (2010). Public health policy for management of hepatitis B virus infection: historical review of recommendations for immunization. Public Health Nurs., 27(2), 148-157.
Custer, B., Sullivan, S., Hazlet T.K., Iloeje U., Veenstra D.L., Kowdley K.V. (2014) Global epidemiology of hepatitis B virus. J. Clin. Gastroenterol., 78, 158-168.
Thio, C. (2013). Hepatitis B in the HIV-infected patient: epidemiology, natural history and treatment. Seminars in Liver Disease, 63, 125-136.
Alter, M.J. (2016). Epidemiology of viral hepatitis and HIV coinfection. Journal of Hepatology, 84 (Suppl. 1), 6-9.
Shao, J., Haukenes, G., Yangi, E., Vollset, S. (2013). Association of hepatitis B and HIV infections in Tanzanian population groups. Eur. J. Clin. Microbiol. Infect. Dis., 82, 62-64.
Uneke, C., Ogbu, O., Inyama, P., Anyanwu, G.I., Njoku, M.O., Idoko, J.H. (2015). Prevalence of hepatitis B surface antigen among blood donors and HIV-infected patients in Jos, Nigeria. Mem. Inst. Oswaldo Cruz., 140, 13-16.
Herasun, B.A. (2009). Virusnyy hepatyt B. HB-virusna infektsiya [Viral Hepatitis B. HB-Viral Infection]: monohrafiya. Lviv: LNMU, 260 p. [In Ukrainian].
Detering, K., Constantinescu, I., Nedelcu, F.D., Gervain, J., Nemecek, V., Srtunecky, O., … Wedemeyer, H. (2008). Prevalence of HBV genotypes in Central and Eastern Europe. J. Med. Virol., 80(10), 1707-1711.
Perez-Olmeda, M., Núñez, M., Garcia-Samaniego, J., Ríos, P., González-Lahoz, J., Soriano, V. (2013). Distribution of HBV genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications. AIDS Res. Hum. Retroviruses, 59, 657-659.
EASL (2017). Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology, 67, 370-398. [E-resourse]: http://www.easl.eu/medias/cpg/management-of-hepatitis-B-virus-infection/English-report.pdf
EASL clinical practice guidelines (2012). Management of chronic hepatitis B virus infection. European Association for the Study of the Liver. J. Hepatol., 57, 167-185.
Mason, W.S., Gill, U.S., Litwin, S., Zhou, Y., Peri, S., Pop, O., … Kennedy, P.T. (2016). HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology, 151, 986-998.
Kennedy. P.T., Sandalova. E., Jo.J., (2012). Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology, 143, 637-645.
Cornberg, M., Wong, V.W., Locarnini, S., Brunetto, M., Janssen, H.L.A., Chan, H.L. (2017). The role of quantitative hepatitis B surface antigen revisited. J. Hepatol., 66, 398-411. [E-resource]. Retrieved from: http://dx.doi.org/10.1016/j.jhep.2016.08.009.
Yang, R., Song, G., Guan, W., Wang, Q., Liu, Y., Wei, L. (2016). The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen. J. Virol. Methods., 228, 39-47.
Kellerman, S., Hanson, D., McNaghten, A., Fleming, P. (2013). Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected subjects. J. Infect. Dis., 228, 571-577.
Bodsworth, N., Cooper, D., Donovan, B. (2011). The influence of HIV-1 infection on the development of the hepatitis B carrier state. J. Infect. Dis., 243, 1138-1140.
Konopnicki, D., Mocroft, A., de Wit, S., Antunes, F., Ledergerber, B., Katlama, C., … EuroSIDA Group. (2015). Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS, 569(6), 593-602.
Puoti, M., Raffaele, B., Soriano, V., Donato, F., Gaeta, G.B., Quinzan, G.P., ... Vaccher, E. (2014). Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS, 58(17), 2285-2293.
Soriano, V., Puoti, M., Bonacini, M. (2015). Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an HTV-HBV international panel. AIDS, 59(3), 221-240.
Lamagni, T., Davison, K., Hope, V. (2009). Poor hepatitis B vaccine coverage in injecting drug users: England, 2005 and 2006. Common Dis. Public Health, 42, 174-177.
Rey, D., Krantz, V., Partisani, M. (2010). Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV infected patients. Effects on HIV-1 viral load. Vaccine, 58, 1161-1165.
Mweemba, A., Zanolini, A., Mulenga, L., Emge, D., Chi, B.H., Wandeler, G., Vinikoor, M.J. (2014). Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-Infected adults. Clin. Infect. Dis., 59(12), 1757-1760.
Chen, C.J., Yang, H.I., Su, J., Jen, C.L., You, S.L., Lu, S.N., Huang, G.T., Iloeje, U.H. (2006). Risk of hepatocellular carcinoma across a biologial gradient of serum hepatitis B virus DNA level. JAMA, 295(l), 65-73.
Rezolyutsiya Pervoy Yevropeyskoy soglasitelnoy konferentsii po lecheniyu khronicheskikh gepatitov B i C u VICH-infitsirovannykh [Resolution of the First European Conciliation Conference on the Treatment of Chronic Hepatitis B and C in HIV-infected individuals]. (2006). Standarty meditsiny, 1, 39-48. [In Russian].
Terrault, N.A., Bzowej, N.H., Chang, K.M., Hwang, J.P., Jonas, M.M., Murad, M.H. (2016). AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 63, 261-283.
Nakaz MOZ Ukrayiny № 613 vid 21.06.2016 r. «Unifikovanyy klinichnyy protokol pervynnoyi, vtorynnoyi (spetsializovanoyi), tretynnoyi (vysokospetsializovanoyi) medychnoyi dopomohy. Virusnyy hepatyt B u doroslykh» [Order of the Ministry of Health of Ukraine No. 613 dated June 21, 2016 «Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical aid. Viral Hepatitis B in Adults]. [E-resource]. Retrieved from: http://mtd.dec.gov.ua/images/dodatki/2016_613_VirysGep_B/2016_613_YKPMD_vgB_dor.pdf [In Ukrainian].
EACS guidelines 8.1 (October 2016) update. – [E-resource]. Retrieved from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
Klinichnyy protokol diahnostyky i likuvannya khronichnykh virusnykh hepatytiv (В, С, D, G). [Clinical protocol for the diagnosis and treatment of chronic viral hepatitis (B, C, D, G)]. (2010). Kyiv, 48 p. [In Ukrainian].
BMJ Best Practice. Hepatitis B. (2015). [E-resource]. Retrieved from: https://bestpractice.bmj.com/topics/uk-ua/127/pdf/127.pdf
European AIDS Clinical Society (2016). Treatment Guidelines, 8, 1. [E-resource]. Retrieved from: http://www.eacsociety.org/files/guidelines_8.1-english.pdf.
Gallant, J., Brunetta, J., Crofoot, G., Benson, P., Mills, A., Brinson, C., … McCallister, S. (2016). Brief report: efficacy and safety of switching to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-1/hepatitis B-coinfected adults. J. Acquir. Immune Defic. Syndr., 73, 294-298.
Panel on Antiretroviral Guidelines for Adults and Adolescents. (2016). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. – [E-resource]. Retrieved from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Panel on Clinical? (December 1, 2015). Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). [E-resource]. Retrieved from: http://AIDSinfo.nih.gov.
HIV and viral hepatitis coinfection (2007). Editor Soriano V. Barselona, Spain: Permanyer Publisher, 118 p.
Rockstroh, J.K., Bhagani, S., Benhamou, Y., Bruno, R., Mauss, S., Peters, L., … Tural, C. (2008). European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Medicine, 9, 82-88.
Lampertico, P., Vigano, M., Di Costanzo, G., Sagnelli, E., Fasano, M., Di Marco, V., … Colombo, M. (2010). Extended (2 years) treatment with peginterferon alfa-2a [40 kd] improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B. Vienna Austria, April 14-18 2010. 45th Annual Meeting of the European Association, for the Study of the Liver (EASL). Vienna Austria, Abstract 98.
Plaza, Z., Aguilera, A., Mena, A., Vispo, E., Sierra-Enguita, R., Tomé, S., ... Poveda, E. (2013). Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. AIDS, 27(14), 2219-2224.
Gallant, J.E., Parish, M.A., Keruly, J.C., Moore, R.D. (2015). Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin. Infect. Dis., 80, 1194-1198.
Cassetti, I., Madruga, J.V., Etzel, A., Etzel, A., Zhong, L., Cheng, A.K., Enejosa, J. (2008). The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral-naive patients through seven years. Mexico City Mexico, August 3-8 2008. Program and abstracts of the 17-th International AIDS Conference. Mexico City Mexico, Abstract TUPE0057.
Collonno, R.J., Rose, R.E., Baldick, C.J., Pokornowski, K., Eggers, B., Plym, M., … Tenney, D.J. (2006). Week 48 Resistance Surveillance of HIV/HBV Co-Infected Patients Treated with Entecavir in Study A1463038. Denver, CO 5-8 February 2006. 13th Conference on Retroviruses and Opportunistic Infections (CROI). Denver CO, Poster 832.
Audsley, J., Sasadeusz, J., Mijch, A. (2008). The Anti-HІV Activity of Entecavir: Serum HIV RNA Decreases and Selection of the MІ 84V Mutation Occurs in both ART-na’ive and – experienced HIV/HBV-co-infected Individuals. February 3-6 Boston, USA. 15-th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, USA, Abstract 63.
World Health Organization. (2013). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva.
Virusnyy hepatyt B. Pozytsiya VOOZ [Viral hepatitis B. The position of WHO]. (2016). Adaptovana klinichna nastanova, zasnovana na dokazakh. 142 p. E-resource: http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/ [In Ukrainian].
Ott, J.J., Stevens, G.A., Groeger, J. Wiersma, S.T. (2012). Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine, 30(12), 2212-2219.
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., … Memish, Z.A. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380(9859), 2095-2128.
Perz, J.F., Armstrong, G.L., Farrington, L.A., Hutin, Y.J., Bell, B.P. (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol., 45(4), 529-538.
Soriano, V., Puoti, M., Sulkowski, M. (2004). Care of Patients with Hepatitis C and HIV Co-Infection. AIDS, 18(1), 1-12.
Pol, S., Trinh, T., Thiers, V. (2005). Chronic hepatitis of drug users: influence of HIV infection. J. Hepatol., 22, Abstract 933.
Sulkowski, M., Thomas, D., Chaisson, R., Moore, R. (2010). Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA, 323, 74-80.
Downloads
Published
Issue
Section
License
Автори, які публікуються у цьому журналі, погоджуються з наступними умовами:
- Автори залишають за собою право на авторство своєї роботи та передають журналу право першої публікації цієї роботи, яка через [ВКАЖІТЬ ПЕРІОД ЧАСУ] з дати публікації автоматично стає доступною на умовах ліцензії Creative Commons Attribution License, котра дозволяє іншим особам вільно розповсюджувати опубліковану роботу з обов'язковим посиланням на авторів оригінальної роботи та першу публікацію роботи у цьому журналі.
- Автори мають право укладати самостійні додаткові угоди щодо неексклюзивного розповсюдження роботи у тому вигляді, в якому вона була опублікована цим журналом (наприклад, розміщувати роботу в електронному сховищі установи або публікувати у складі монографії), за умови збереження посилання на першу публікацію роботи у цьому журналі.
Політика журналу дозволяє і заохочує розміщення авторами в мережі Інтернет (наприклад, у сховищах установ або на особистих веб-сайтах) рукопису роботи, як до подання цього рукопису до редакції, так і під час його редакційного опрацювання, оскільки це сприяє виникненню продуктивної наукової дискусії та позитивно позначається на оперативності та динаміці цитування опублікованої роботи (див. The Effect of Open Access).
